ストックスクリーナーアプリを入手
128.23
6.24%
-8.53
前日終値:
$136.76
開ける：
$137.1
24時間の取引高:
2.91M
Relative Volume:
2.61
時価総額：
$12.69B
収益：
$2.41B
当期純損益:
$305.80M
株価収益率:
43.47
EPS:
2.95
ネットキャッシュフロー:
$492.20M
1週間 パフォーマンス:
-2.59%
1か月 パフォーマンス:
+2.02%
6か月 パフォーマンス:
-15.54%
1年 パフォーマンス:
-9.42%
1日の値動き範囲:
$127.25
$137.44
1週間の範囲:
$127.25
$137.44
52週間の値動き範囲:
$84.23
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
名前
Neurocrine Biosciences Inc
セクター
電話
(858) 617-7600
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
NBIX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2025-04-15 | アップグレード | Needham | Hold → Buy |
| 2025-04-14 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-08-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 再開されました | Citigroup | Neutral |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 繰り返されました | Mizuho | Neutral |
| 2023-07-24 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-30 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-02-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-09-26 | 開始されました | Wells Fargo | Equal Weight |
| 2022-06-06 | 再開されました | Jefferies | Buy |
| 2022-03-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-18 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Underperform |
| 2021-11-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 再開されました | Needham | Hold |
| 2021-08-06 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 再開されました | Goldman | Neutral |
| 2021-05-06 | アップグレード | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 開始されました | Raymond James | Outperform |
| 2020-09-30 | 開始されました | The Benchmark Company | Hold |
| 2020-08-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-06-29 | ダウングレード | Goldman | Buy → Neutral |
| 2020-06-09 | 開始されました | Wedbush | Outperform |
| 2020-03-06 | 開始されました | Citigroup | Buy |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-24 | 開始されました | William Blair | Outperform |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-13 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-05 | 開始されました | Guggenheim | Neutral |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-02-06 | 繰り返されました | BofA/Merrill | Buy |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 開始されました | Goldman | Buy |
| 2018-11-21 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Neurocrine Biosciences Inc (NBIX) 最新ニュース
Neurocrine (NBIX) Q2 Revenue Jumps 17% - The Motley Fool
Neurocrine (NBIX) Q2 Revenue Jumps 17% - Nasdaq
The Analyst Verdict: Neurocrine Biosciences In The Eyes Of 17 Experts - 富途牛牛
Guggenheim raises Neurocrine Bio. stock price target on strong Ingrezza sales - Investing.com Canada
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
Neurocrine Bio. price target raised to $145 from $140 at Mizuho - Investing.com Canada
Neurocrine Biosciences Positioned For Growth And New Potential Blockbusters (NASDAQ:NBIX) - Seeking Alpha
Neurocrine Bio. stock price target raised by BMO Capital to $124 - Investing.com
Neurocrine refines INGREZZA net sales guidance to $2.5B-$2.55B while CRENESSITY surges, driving revenue growth and pipeline expansion - MSN
Neurocrine: Q2 Earnings Snapshot - CTPost
Strong Earnings and Pipeline Progress Could Be a Game Changer for Neurocrine Biosciences (NBIX) - simplywall.st
Neurocrine Biosciences 2025 Q2 Earnings Strong Growth as Net Income Rises 65.4% - AInvest
Neurocrine Biosciences (NBIX): Navigating Pricing Pressures While Delivering Strong Sales Growth in Q2 2025 - AInvest
Neurocrine Biosciences Inc (NBIX) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada
Schizophrenia Market Size 2034: Clinical Trials, EMA, PDMA, FDA - openPR.com
Neurocrine Biosciences' Strategic Momentum in Movement Disorder Therapies: A Deep Dive into INGREZZA's Sustained Growth and CRENESSITY's Emerging Potential - AInvest
Neurocrine Biosciences, Inc. 2025 Q2 Earnings and Strategic Momentum: A Deep Dive into Long-Term Growth Potential - AInvest
Earnings call transcript: Neurocrine Biosciences Q2 2025 earnings beat expectations - Investing.com Australia
Earnings call transcript: Neurocrine Biosciences Q2 2025 earnings beat expectations By Investing.com - Investing.com South Africa
Neurocrine Biosciences' Q2 2025 Outperformance: A Case for Sustainable Growth and Premium Valuation - AInvest
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings - Yahoo Finance
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates - Nasdaq
Neurocrine Biosciences Inc Q2 Profit Increases, Beats Estimates - Nasdaq
Neurocrine Q2 2025 slides: revenue growth accelerates, pipeline expands By Investing.com - Investing.com South Africa
Neurocrine Biosciences Reports Second Quarter 2025 Financial Results - PR Newswire
Published on: 2025-07-30 15:28:02 - metal.it
Neurocrine reports positive results from Crenessity trial - MSN
Published on: 2025-07-29 10:29:58 - metal.it
Neurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence - MSN
Endometriosis Market Predicted to See Upsurge Through 2034, - openPR.com
How Neurocrine Biosciences Inc. stock performs during market volatilityFree Membership Group - metal.it
Endometriosis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Ferring Pharma, AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharma, Enteris BioPharma - Barchart.com
How volatile is Neurocrine Biosciences Inc. stock compared to the marketCapitalize on market momentum for profits - jammulinksnews.com
What makes Neurocrine Biosciences Inc. stock price move sharplyMarket-beating returns - jammulinksnews.com
Is Neurocrine Biosciences Inc. a growth stock or a value stockUnlock real-time trading signals for gains - jammulinksnews.com
Why is Neurocrine Biosciences Inc. stock attracting strong analyst attentionMaximize gains with proven stock analysis - jammulinksnews.com
Is Neurocrine Biosciences Inc. stock overvalued or undervaluedFree Stock Market Query - jammulinksnews.com
What institutional investors are buying Neurocrine Biosciences Inc. stockInvest confidently with daily market forecasts - jammulinksnews.com
How strong is Neurocrine Biosciences Inc. company’s balance sheetBuild a diversified portfolio for steady growth - jammulinksnews.com
Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating - MSN
Is Neurocrine Biosciences Inc. stock overhyped or has real potentialExponential wealth increase - jammulinksnews.com
10 Best Strong Buy Healthcare Stocks to Buy Now - Insider Monkey
Is Neurocrine Biosciences Inc. a good long term investmentRecord-breaking gains - Autocar Professional
Neurocrine Biosciences (NASDAQ:NBIX) Earns Buy Rating from Analysts at Truist Financial - MarketBeat
What analysts say about Neurocrine Biosciences Inc. stockDynamic investment opportunities - Autocar Professional
Neurocrine Biosciences Inc (NBIX) 財務データ
収益
当期純利益
現金流量
EPS
2.57%
0.85%
大文字化:
|
ボリューム (24 時間):